siremadlin + cytarabine + midazolam

This is a combination regimen consisting of siremadlin (HDM201), cytarabine, and midazolam. Siremadlin is a small molecule, orally bioavailable inhibitor of human double minute 2 homolog (HDM2/MDM2), designed to disrupt the MDM2-p53 interaction and restore p53-mediated tumor suppression, leading to apoptosis in p53 wildtype cancer cells. Cytarabine is a pyrimidine nucleoside analog used as a chemotherapeutic agent, inhibiting DNA synthesis in rapidly dividing cells; it is primarily used in the treatment of hematologic malignancies such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Midazolam is a short-acting benzodiazepine used for sedation, anesthesia induction, and seizure management, acting as a positive allosteric modulator at the GABA-A receptor. This specific combination is investigational and may be used in research settings related to hematological malignancies, especially AML, given siremadlin’s evaluation in AML in clinical trials and the use of cytarabine as standard-of-care chemotherapy. The inclusion of midazolam is likely for procedural or supportive care, such as sedation during administration.